SCHEMBL2836775

SCHEMBL2836775

C=CCCCCCCCCCCCCCCCCCO

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.52
ABCC4 O15439 1/20 0.50
MAPT P10636 1/20 0.50
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
LPAR3 Q9UBY5 2/20 0.43
LPAR2 Q9HBW0 1/20 0.43
TRPA1 O75762 2/20 0.41
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
USP2 O75604 1/20 0.36
SLC2A1 P11166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2531568 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL8999819 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL129386 1.00
SCHEMBL41157 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL129761 1.00
SCHEMBL530923 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL128643 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL129678 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL2834305 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA
SCHEMBL10718401 1.00 TSHR (0.52) TSHRABCC4MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3129347-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES California Institute of Technology (US) 2017-02-15 EP claimed
WO-2015157736-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-10-15 WO claimed
US-20150284313-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-08 US claimed
US-20260035391-A1 SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2026-02-05 US disclosed
EP-4678645-A1 SILANE COMPOUND Daikin Industries, Ltd. (JP) 2026-01-14 EP disclosed
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-11-27 US disclosed
WO-2025028568-A1 SURFACE TREATMENT AGENT ダイキン工業株式会社 2025-02-06 WO disclosed
WO-2024214748-A1 SILANE COMPOUND ダイキン工業株式会社 2024-10-17 WO disclosed
WO-2024185688-A1 FLUORINATED POLYMER ダイキン工業株式会社 2024-09-12 WO disclosed
WO-2024185707-A1 FLUORINE-CONTAINING COMPOUND ダイキン工業株式会社 2024-09-12 WO disclosed
WO-2024185687-A1 FLUORINE-CONTAINING COMPOUND ダイキン工業株式会社 2024-09-12 WO disclosed
US-20130158277-A1 PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS BIOSYN HOLDINGS, LLC 2013-06-20 US disclosed
US-20100145086-A1 Synthesis of Terminal Alkenes From Internal Alkenes Via Olefin Metathesis ELEVANCE RENEWABLE SCIENCES, INC. 2010-06-10 US disclosed
EP-2076484-A2 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS Elevance Renewable Sciences, Inc. (US) 2009-07-08 EP disclosed
WO-2008046106-A2 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS ELEVANCE RENEWABLE SCIENCES, INC. (US) 2008-04-17 WO disclosed
EP-0341773-B1 Process for the preparation of lactones SHELL INT RESEARCH (NL) 1996-09-11 EP disclosed
US-5128438-A Polymerization of carbon monoxide and ethylenically unsaturated carboxylic acid SHELL OIL COMPANY (US) 1992-07-07 US disclosed
US-5025092-A Polymerization of carbon monoxide with ethylenically unsaturated alcohol SHELL OIL COMPANY (US) 1991-06-18 US disclosed
US-4960906-A Process for the preparation of lactones from higher alkenols SHELL OIL COMPANY (US) 1990-10-02 US disclosed
EP-0341773-A1 Process for the preparation of lactones SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1989-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158277-A1 PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS SQLE, ALOX12, ALOX15 TSHR 3783/4885ABCC4 4321/4885MAPT 2801/4885
US-20260035391-A1 SILANE COMPOUND OXER1, CBR1, MSR1 TSHR 1167/4885ABCC4 3555/4885MAPT 3787/4885
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND FLI1, AFF1, RFT1 TSHR 2035/4885ABCC4 4730/4885MAPT 4711/4885
US-20150284313-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES DDC, LTC4S, CYCS TSHR 4169/4885ABCC4 1599/4885MAPT 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.